Last reviewed · How we verify

Rivaroxaban 10 milligram Oral Tablet

Florida Orthopaedic Institute · FDA-approved active Small molecule

Rivaroxaban 10 milligram Oral Tablet is a Direct Factor Xa inhibitor Small molecule drug developed by Florida Orthopaedic Institute. It is currently FDA-approved for Prophylaxis of deep vein thrombosis and pulmonary embolism following hip or knee replacement surgery, Treatment of deep vein thrombosis and pulmonary embolism, Stroke prevention in patients with atrial fibrillation. Also known as: Xarelto.

Rivaroxaban is a direct Factor Xa inhibitor that blocks a key enzyme in the blood coagulation cascade, preventing thrombin generation and clot formation.

Rivaroxaban is a direct Factor Xa inhibitor that blocks a key enzyme in the blood coagulation cascade, preventing thrombin generation and clot formation. Used for Prophylaxis of deep vein thrombosis and pulmonary embolism following hip or knee replacement surgery, Treatment of deep vein thrombosis and pulmonary embolism, Stroke prevention in patients with atrial fibrillation.

At a glance

Generic nameRivaroxaban 10 milligram Oral Tablet
Also known asXarelto
SponsorFlorida Orthopaedic Institute
Drug classDirect Factor Xa inhibitor
TargetFactor Xa
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Rivaroxaban selectively inhibits Factor Xa, a serine protease central to both the intrinsic and extrinsic pathways of the coagulation cascade. By blocking Factor Xa, the drug prevents the conversion of prothrombin to thrombin, thereby reducing thrombin-mediated fibrin clot formation. This anticoagulant effect is used to prevent and treat thrombotic events.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Rivaroxaban 10 milligram Oral Tablet

What is Rivaroxaban 10 milligram Oral Tablet?

Rivaroxaban 10 milligram Oral Tablet is a Direct Factor Xa inhibitor drug developed by Florida Orthopaedic Institute, indicated for Prophylaxis of deep vein thrombosis and pulmonary embolism following hip or knee replacement surgery, Treatment of deep vein thrombosis and pulmonary embolism, Stroke prevention in patients with atrial fibrillation.

How does Rivaroxaban 10 milligram Oral Tablet work?

Rivaroxaban is a direct Factor Xa inhibitor that blocks a key enzyme in the blood coagulation cascade, preventing thrombin generation and clot formation.

What is Rivaroxaban 10 milligram Oral Tablet used for?

Rivaroxaban 10 milligram Oral Tablet is indicated for Prophylaxis of deep vein thrombosis and pulmonary embolism following hip or knee replacement surgery, Treatment of deep vein thrombosis and pulmonary embolism, Stroke prevention in patients with atrial fibrillation, Acute coronary syndrome.

Who makes Rivaroxaban 10 milligram Oral Tablet?

Rivaroxaban 10 milligram Oral Tablet is developed and marketed by Florida Orthopaedic Institute (see full Florida Orthopaedic Institute pipeline at /company/florida-orthopaedic-institute).

Is Rivaroxaban 10 milligram Oral Tablet also known as anything else?

Rivaroxaban 10 milligram Oral Tablet is also known as Xarelto.

What drug class is Rivaroxaban 10 milligram Oral Tablet in?

Rivaroxaban 10 milligram Oral Tablet belongs to the Direct Factor Xa inhibitor class. See all Direct Factor Xa inhibitor drugs at /class/direct-factor-xa-inhibitor.

What development phase is Rivaroxaban 10 milligram Oral Tablet in?

Rivaroxaban 10 milligram Oral Tablet is FDA-approved (marketed).

What are the side effects of Rivaroxaban 10 milligram Oral Tablet?

Common side effects of Rivaroxaban 10 milligram Oral Tablet include Bleeding, Gastrointestinal bleeding, Intracranial hemorrhage, Syncope.

What does Rivaroxaban 10 milligram Oral Tablet target?

Rivaroxaban 10 milligram Oral Tablet targets Factor Xa and is a Direct Factor Xa inhibitor.

Related